Andrea Tesvich Murina, MD, FAAD
SESSIONS
F030 How to Approach Challenges in Hidradenitis Suppurativa Management: Strategies to Optimize Use of HS Therapies
Mar 8, 2025
•
9:00 AM - 11:00 AM
•
Valencia Ballroom A
U045 Combining Systemic Therapies: Should You Do It?
Mar 8, 2025
•
4:30 PM - 5:30 PM
•
Valencia Ballroom A
HANDOUTS
Login to view handouts
DISCLOSURES
AbbVie – Speaker(Honoraria); Amgen – Speaker(Honoraria); Boehringer Ingelheim – Consultant (1099 relationship)(Honoraria); Botanix Pharmaceuticals – Speaker(Honoraria); Bristol-Myers Squibb – Speaker(Honoraria); Eli Lilly and Company – Speaker(Honoraria); Galderma – Speaker(Honoraria); Janssen Biotech – Speaker(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria); Ortho Dermatologics – Advisory Board(Honoraria), Speaker(Honoraria); Pfizer Inc. – Speaker(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); UCB – Advisory Board(Honoraria); UCB Pharma – Speaker(Honoraria);